Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03069469 · ClinicalTrials.gov registry record · Phase 1
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
A Phase 1 study of Advanced Malignant Neoplasm and Tenosynovial Giant Cell Tumor, sponsored by Deciphera Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT03069469: Active Phase 1 study of Advanced Malignant Neoplasm and Tenosynovial Giant Cell Tumor, sponsored by Deciphera Pharmaceuticals.
NCT03069469 is a Phase 1 study of Advanced Malignant Neoplasm and Tenosynovial Giant Cell Tumor that is active but no longer recruiting, run by Deciphera Pharmaceuticals. The registered enrollment target is 120 participants, below the 169-participant average among 16 other Advanced Malignant Neoplasm trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03069469, a Phase 1 study of Advanced Malignant Neoplasm and Tenosynovial Giant Cell Tumor, is active but no longer recruiting, sponsored by Deciphera Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.
Primary Outcome
Determine the maximum tolerated dose.
Conditions Studied
Interventions
- DRUG Vimseltinib
Study Locations (20)
Other
- Peter MacCallum Cancer Centre - Melbourne
- Princess Margaret Cancer Center - Toronto
- Centre Leon Berard - Lyon
- Gustave Roussy Cancer Campus Grand Paris - Paris
- IRCCS Istituto Ortopedico Rizzoli - Bologna
- Fondazione IRCCS Istituto Nazionale Dei Tumori - Milan
- Istituto Nazionale dei Tumori - Milan
- Regina Elena National Cancer Institute - Rome
- Leiden University Medical Center - Leiden
- M. Sklodowska-Curie Memorial Cancer Center - Warsaw
Florida
- Mayo Clinic - Jacksonville
- University of Miami - Miami
Oregon
- OHSU - Portland
- Oregon Health & Science University - Portland
California
- Stanford Cancer Institute - Palo Alto
Colorado
- University of Colorado - Denver - Denver
Massachusetts
- Dana Farber - Boston
New York
- MSKCC - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-02-16 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
What the registry record for NCT03069469 still lists
NCT03069469 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 169-participant average among 16 other Advanced Malignant Neoplasm trials with a reported enrollment target (29% lower).
The record links to 5 conditions, with Advanced Malignant Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Vimseltinib is the first listed.
NCT03069469 names 20 study sites across 9 states, led by Other, Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT03069469 about?
NCT03069469 is a clinical study titled "Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor". This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT ...
What is the current status of trial NCT03069469?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2017-02-16. Estimated completion is 2028-08.
What conditions does trial NCT03069469 study?
This clinical trial studies the following conditions: Advanced Malignant Neoplasm, Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse.
What interventions are being tested in trial NCT03069469?
The interventions under investigation include: Vimseltinib (DRUG).
Who is sponsoring clinical trial NCT03069469?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03069469 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03069469's enrollment target sits among peer trials
120 12th of 16 higher than 5 of 16 other Advanced Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RECRUITING · Phase 1
-
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
ACTIVE NOT RECRUITING · Phase 1
-
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI